Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Healthy ExtractsHYEX 58 3-Year EBITDA Growth Rate is 35.70% as of Jun. 2026, which is 36% below its 10-year median of 55.80. GuruFocus rates HYEX with a GF Score™ of 58/100 and a GF Value™ of $1.14 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 805 Drug Manufacturers companies, Healthy Extracts ranks better than 82.24% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 35.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 43.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Healthy Extracts was 86.40% per year. The lowest was 15.20% per year. And the median was 55.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Healthy Extracts 3-Year EBITDA Growth Rate Related Terms
HYEX vs IGPK, CABR, BFRI: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Healthy Extracts's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healthy Extracts 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Healthy Extracts's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Healthy Extracts's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 35.70% mean?
Healthy Extracts (HYEX) has a 3-Year EBITDA Growth Rate of 35.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Healthy Extracts and its competitors. This is 36% below median its historical median of 55.80. Over the past decade, Healthy Extracts' 3-Year EBITDA Growth Rate has ranged from 15.20 to 86.40. According to the industry distribution chart, Healthy Extracts ranks #143 out of 805 companies in the Drug Manufacturers industry, placing it in the top 17.8%.
Is Healthy Extracts' 3-Year EBITDA Growth Rate too high?
Healthy Extracts' current 3-Year EBITDA Growth Rate of 35.70% is 36% below median its 10-year median of 55.80. Over the past 10 years, this metric has ranged from a low of 15.20 to a high of 86.40. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Healthy Extracts' value of 35.70% is 301.1% above this industry median. Based on the distribution chart, Healthy Extracts ranks #143 out of 805 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Healthy Extracts has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Healthy Extracts' 3-Year EBITDA Growth Rate compare to IGPK and CABR?
According to the Drug Manufacturers industry distribution chart, Healthy Extracts ranks #143 out of 805 companies for 3-Year EBITDA Growth Rate. This places Healthy Extracts in the top 18% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Healthy Extracts' value of 35.70% is 301.1% above this benchmark. Historically, Healthy Extracts' own 3-Year EBITDA Growth Rate has ranged from 15.20 to 86.40 over the past decade. While the company's 10-year median is 55.80 vs. the industry median of 8.90, Healthy Extracts has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healthy Extracts's current 3-Year EBITDA Growth Rate of 35.70% is 301.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Healthy Extracts and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healthy Extracts's current 3-Year EBITDA Growth Rate is 35.70%, which is 36% below median its own 10-year median of 55.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healthy Extracts stock overvalued right now?
Based on GuruFocus' analysis, Healthy Extracts (HYEX) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.14, compared to a current price of $0.90 — trading 21.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 35.70%, which is 36% below median its 10-year median of 55.80 and 301.1% above the Drug Manufacturers industry median of 8.90. Healthy Extracts' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Healthy Extracts (HYEX), the current 3-Year EBITDA Growth Rate is 35.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healthy Extracts (HYEX) Overvalued in 2026?
Based on GuruFocus' analysis, Healthy Extracts stock appears to be undervalued.
The current stock price of $0.90 is trading 21.1% below its estimated GF Value™ of $1.14.
GuruFocus considers Healthy Extracts to be Modestly Undervalued.
Key valuation signals for HYEX:
3-Year EBITDA Growth Rate: 35.70% (36% below median its 10-year median of 55.80)
GF Value™: $1.14 vs. price of $0.90 (21.1% below fair value)
Industry Position: 301.1% above the Drug Manufacturers median (#143 of 805)
No single metric tells the full story. See the HYEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healthy Extracts Inc through its subsidiaries is engaged in proprietary research and development of natural plant-based formulations, manufacturing, sales, and distribution of cardiovascular and neuro products that provide natural brain solutions. The company also provides superfruit supplements to support overall cholesterol, metabolic and cardiovascular health. Its products are distributed in the United States and Mexico. Its operating segment includes, Health Supplements and Corporate. The company generates maximum revenue from the Health Supplements segment.
58GF Score
Get the complete analysis for HYEX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HYEX has been successfully added to your 
